AGEN Key Statistics, Chart & Performance
The current stock price of AGEN is 3.91 USD. In the past month the price decreased by -4.4%. In the past year, price increased by 25.52%.
AGEN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About AGEN
Company Profile
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Company Info
AGENUS INC
3 Forbes Rd
Lexington MASSACHUSETTS 02421 US
CEO: Garo H. Armen
Employees: 316
Phone: 17816744400
AGENUS INC / AGEN FAQ
Can you describe the business of AGENUS INC?
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2000-02-04. The Company’s pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is immuno-oncology (I-O), and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody) and balstilimab (a novel, fully human monoclonal immunoglobulin G4 (IgG4) PD-1 inhibitor). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Can you provide the latest stock price for AGENUS INC?
The current stock price of AGEN is 3.91 USD. The price increased by 4.27% in the last trading session.
Does AGEN stock pay dividends?
AGEN does not pay a dividend.
How is the ChartMill rating for AGENUS INC?
AGEN has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Where is AGENUS INC (AGEN) stock traded?
AGEN stock is listed on the Nasdaq exchange.
What is the next earnings date for AGEN stock?
AGENUS INC (AGEN) will report earnings on 2026-03-09, after the market close.
What is the outstanding short interest for AGENUS INC?
The outstanding short interest for AGENUS INC (AGEN) is 8.3% of its float.
AGEN Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to AGEN. When comparing the yearly performance of all stocks, AGEN turns out to be only a medium performer in the overall market: it outperformed 65.94% of all stocks.
AGEN Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to AGEN. AGEN has a bad profitability rating. Also its financial health evaluation is rather negative.
AGEN Financial Highlights
Over the last trailing twelve months AGEN reported a non-GAAP Earnings per Share(EPS) of -2.13. The EPS increased by 81.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.13% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
AGEN Forecast & Estimates
9 analysts have analysed AGEN and the average price target is 12.58 USD. This implies a price increase of 221.74% is expected in the next year compared to the current price of 3.91.
For the next year, analysts expect an EPS growth of 109.04% and a revenue growth 59.32% for AGEN